鶹ýɫƬ

Journal News

Proteomic variation in heart tissues

Ecem Arpaci
By Ecem Arpaci
June 17, 2025

Induced pluripotent stem cells, or iPSCs, can be used to model tissues and disorders, such as heart diseases. However, the human heart is complex, with several regions and cell types. Therefore, analyzing single cardiac cells can be challenging.

Lizhuo Ai, Aleksandra Binek and Vladimir Zhemkov of the Cedars-Sinai Medical Center and a team in the U.S. used this approach to analyze heart cells throughout various stages of development. They published their in 鶹ýɫƬ & Cellular Proteomics. The authors differentiated iPSCs into cardiomyocytes, the muscle cells of the heart, and analyzed their proteome at various time points using mass spectrometry.

Berkshire Community College Bioscience Image Library

The team detected proteomic differences between groups of iPSC-derived cardiomyocytes, or iCMs, at the end of their three-week differentiation period, suggesting that they had developed into multiple cell subtypes. Many differentially expressed proteins between two of these subtypes functioned in extracellular vesicles, called exosomes, which transport biomolecules such as DNA and proteins to other cells. They also compared iCMs to those isolated from adult human hearts, or aCMs. They found the two cell types shared many proteins involved in muscle function, but that aCMs had a higher proportion of mitochondrial proteins, suggesting that iCMs are metabolically immature.

Furthermore, detailed analysis revealed that a few human adult heart cells expressed markers that traditionally identify heart and brain cells, which may represent a newly discovered cell type. These results could mean that heart cells are more diverse than scientists originally thought and could underlie some functions such as exosome formation. The ability of iCMs to recreate much of the cardiomyocyte proteome, combined with the diversity of tissues they produce, make iPSCs appealing candidates for studying and treating human heart diseases.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ecem Arpaci
Ecem Arpaci

Ecem Arpaci is a biochemistry student at Imperial College London and a research intern at Radboud University Medical Center. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.